Fulgent Genetics, Inc. (FLGT) News
Filter FLGT News Items
FLGT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest FLGT News From Around the Web
Below are the latest news stories about FULGENT GENETICS INC that investors may wish to consider to help them evaluate FLGT as an investment opportunity.
The 3 Best Digital Health Stocks for Personalized MedicineDigital health stocks are becoming increasingly relelvant as more and more people seek greater control over their health. |
Fulgent to Participate in the Piper Sandler 35th Annual Healthcare ConferenceEL MONTE, Calif., November 14, 2023--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that members of its management team are scheduled to participate in the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023. |
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q3 2023 Earnings Call TranscriptFulgent Genetics, Inc. (NASDAQ:FLGT) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Hello, and welcome to the Fulgent Genetics Q3 2023 Earnings Conference Call and Webcast. [Operator Instructions] A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It’s now my pleasure to turn the call […] |
Q3 2023 Fulgent Genetics Inc Earnings CallQ3 2023 Fulgent Genetics Inc Earnings Call |
Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual MeetingEL MONTE, Calif., November 03, 2023--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced data from two poster presentations being presented tomorrow, November 4, 2023, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA. |
Fulgent Genetics Inc (FLGT) Reports Q3 2023 Financial ResultsCore Revenue Grows 17% YoY, Total Revenue Hits $85 Million |
Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Tops Revenue EstimatesFulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of -21.88% and 31.46%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
Fulgent Reports Third Quarter 2023 Financial ResultsEL MONTE, Calif., November 03, 2023--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2023. |
Fulgent Genetics, Inc. (NASDAQ:FLGT) is definitely on the radar of institutional investors who own 47% of the companyKey Insights Significantly high institutional ownership implies Fulgent Genetics' stock price is sensitive to their... |
Top 20 Genomics Companies in the WorldIn this piece, we will take a look at the top 20 genomics companies in the world. If you want to skip our analysis of the genomics industry, then take a look at the Top 5 Genomics Companies in the World. Modern day science has delivered a plethora of advancements that have enabled humans to […] |